/https://specials-images.forbesimg.com/imageserve/607003d5d7b77c9bc0b3cff2/0x0.jpg)
Amgen stated Thursday it will acquire 5 Prime Rehabs for $1.9 billion to acquire a prospective treatment for stomach cancer, a relocation that will likewise broaden the biotech giant’s focus in Asia.
The offer represents a significant triumph for 5 Prime, which traded as low as $2.17 last March. The business’s stock leapt in November, when essential arise from a research study of its stomach cancer drug, bemarituzumab, were launched, and have actually continued to increase considering that.
What is it?
STAT+ is STAT’s premium membership service for thorough biotech, pharma, policy, and life science protection and analysis.
Our acclaimed group covers news on Wall Street, policy advancements in Washington, early science advancements and scientific trial outcomes, and healthcare interruption in Silicon Valley and beyond.
What’s consisted of?
- Daily reporting and analysis
- The most extensive market protection from a powerhouse group of press reporters
- Subscriber-only newsletters
- Daily newsletters to inform you on the most crucial market news of the day
- STAT+ Discussions
- Weekly chances to engage with our press reporters and leading market specialists in live video discussions
- Special market occasions
- Premium access to subscriber-only networking occasions around the nation
- The very best press reporters in the market
- The most relied on and well-connected newsroom in the healthcare market
- And far more
- Special interviews with market leaders, profiles, and premium tools, like our CRISPR Trackr.
